Introduction and background {#Sec1}
===========================

As a discipline, neuroethics addresses and engages a number of topics that are generated by the intersection of brain science and applications in philosophy, medicine, law, public life, and society (on the local and global scales). In Part 2 of this bibliography \[[@CR1]\], we provided a list of works in the scholarly literature that address the neuroscientific basis of moral decision-making and actions, viz.- what Roskies somewhat colloquially refers to as the "neuroscience of ethics" \[[@CR2]\]. In Part 3, we herein present a listing of works that discuss the "ethics of neuroscience," namely those issues, questions and dilemmas generated by current and proposed neuroscientific research and its varied uses. The following bibliographies provide systematic surveys from 2002 to 2014 of the neuroethics literature on translational neuroscience, from "bench to bedside -- and beyond" \[[@CR3], [@CR4]\] To be sure, the topics are numerous, and list of works is long, and include the following subjects:General issues in neuroscience researchNeuroimagingNeurogeneticsNeurobiomarkersNeuro-psychopharmacologyanti-depressants; antipsychotic and nootropic agentsanti-anxiety agentsanalgesicsBrain stimulation/neuromodulationneurofeedbacktranscranial brain stimulation/neuromodulation(i.e.: transcranial direct current stimulation,tDCS; transcranial alternating current stimulation, tACS; and transcranial magnetic stimulation, TMS)deep brain stimulation (DBS)brain-machine interfaces and neural prostheticsNeural stem cells and tissue transplantsIssues concerning pediatric subjects/patientsDual-use neuroscientific research

The topics covered involve defining the ethical issues at hand, assessing patient outcomes, and deliberating on quality of life considerations. These neuroethical deliberations also focus on philosophical concepts such as personhood, authenticity, and identity \[[@CR5], [@CR6]\]. As an analytical approach and discipline, neuroethics is both pragmatic and pluralistic in its focus and scope \[[@CR7]\]. The pragmatism inherent in neuroethics acknowledges "...the contingency of any/all neuroscientific knowledge, and an advocacy for its use *mutatis mutandis*, irrespective of whatever field" to which brain science is applied \[[@CR8]\]. In its pluralistic stance, neuroethics is increasingly oriented toward, acknowledging and respectful of, and employing multi-cultural perspectives, ideas, values, needs, contexts and methods, as relevant to the realities of international neuroscientific research and use upon the twenty first century world stage \[[@CR9]--[@CR13]\].

As with Parts 1 and 2, we regard this as a "participatory bibliography" to which readers are encouraged to submit additional cites via the "Comments" section of this paper, or by contacting the bibliographic manager at bioethics\@georgetown.edu. Through this process, the bibliography can be and remain as current and accurate as possible, so as to keep pace with ongoing developments in neuroscience, their translational use(s) in practice, and the ethical discourses and debates they foster.

Methods {#Sec2}
=======

Methods for systematically searching relevant literature devoted to neuroethics are identical to those utilized in Parts 1 and 2 of this bibliography \[[@CR1], [@CR14]\]. The United States National Library of Medicine's (NLM) indexing language--MeSH (Medical Subject Headings)--was used to generate the basic search strategy for each topic. MeSH contains ethics-related terms developed for BIOETHICSLINE, a specialty database devoted to bioethical issues produced for NLM by the Kennedy Institute of Ethics from 1975 to 2000.

The following databases were utilized:PubMed ([https://pubmed.gov](https://pubmed.gov/))The NLM Catalog (<http://www.ncbi.nlm.nih.gov/nlmcatalog>)Academic Search PremierProquest Research LibraryJSTORLexisNexis AcademicWorldCat ([http://www.worldcat.org](http://www.worldcat.org/))Philosopher's IndexEmbaseBELIT (<http://www.drze.de/belit/>)Web of Knowledge/Web of Science (WoS)Digital Public Library of America (DPLA) (<https://dp.la/>)Directory of Open Access Journals (DOAJ) (<https://doaj.org/>)Hathi Trust Digital Library (<https://www.hathitrust.org/>)European Library (<http://www.theeuropeanlibrary.org/tel4/>)Internet Archive (<https://archive.org/>)Globethics.net (<http://www.globethics.net/>)Neuroethics-Wikiography (<https://teamweb.uni-mainz.de/fb05/Neuroethics>)Law and Neuroscience Bibliography (<http://www.lawneuro.org/bibliography.php>)

Open access bioethics journals not contained in the Directory of Open Access Journals (DOAJ) were individually accessed and searched; these included:Journal of Ethics and Social Philosophy from the University of Southern California (<http://www.jesp.org/>)Journal of Mental Health Ethics from McMaster University (<http://www.jemh.ca/>)Journal of Practical Ethics (<http://www.jpe.ox.ac.uk/>) from the Oxford Uehiro Centre for Practical Ethics at the University of Oxford; andPhilosophers' Imprint from the University of Michigan (<http://www.philosophersimprint.org/>).

Results {#Sec3}
=======

The following bibliographies provide listings of 1137 articles, 56 books, and 134 book chapters published from 2002 through 2014 that focus on the ethical issues involved in translating neuroscientific research to clinical practice.

***Research general issues:***Abi-Rached JM: **The implications of the new brain sciences. The \'Decade of the Brain\' is over but its effects are now becoming visible as neuropolitics and neuroethics, and in the emergence of neuroeconomies**. *EMBO Rep* 2008, **9**(12):1158-1162. doi: 10.1038/embor.2008.211.Alpert S: **Total information awareness---forgotten but not gone: lessons for neuroethics**. *Am J Bioeth* 2007, **7**(5): 24-26.Anderson JA, Eijkholt M, Illes J: **Neuroethical issues in clinical neuroscience research**. *Handb Clin Neurol* 2013, **118**: 335-343. doi: 10.1016/B978-0-444-53501-6.00028-7.Bergareche AM, da Rocha AC: **Autonomy beyond the brain: what neuroscience offers to a more interactive, relational bioethics**. *AJOB Neurosci* 2011, **2**(3): 54-56. doi: 10.1080/21507740.2011.584948.Bird S: **Potential for bias in the context of neuroethics: commentary on "Neuroscience, neuropolitics and neuroethics: the complex case of crime, deception and FMRI"**. *Sci Eng Ethics* 2012, **18**(3): 593-600. doi: 10.1007/s11948-012-9399-y.Blakemore C et al.: **Implementing the 3Rs in neuroscience research: a reasoned approach**. *Neuron* 2012, **75**(6):948-950. doi: 10.1016/j.neuron.2012.09.001.Brosnan C, Cribb A, Wainwright SP, Williams C: **Neuroscientists' everyday experiences of ethics: the interplay of regulatory, professional, personal and tangible ethical spheres.***Sociol Health Illn* 2013, **35**(8): 1133-1148. doi: 10.1111/1467-9566.12026.Caulfield T, Ogbogu U: **Biomedical research and the commercialization agenda: a review of main considerations for neuroscience**. *Account Res* 2008, **15**(4): 303-320. doi: 10.1080/08989620802388788.Chatterjee A: **The ethics of neuroenhancement**. *Handb Clin Neurol* 2013, **118**: 323-34. doi: 10.1016/B978-0-444-53501-6.00027-5.Cheshire WP: **Neuroscience, nuance, and neuroethics**. *Ethics Med* 2006, **22**(2): 71-3.Cheung EH: **A new ethics of psychiatry: neuroethics, neuroscience, and technology**. *J Psychiatr Pract* 2009, **15**(5): 391-401. doi: 10.1097/01.pra.0000361279.11210.14.Choudhury S, Nagel SK, Slaby J: **Critical neuroscience: linking neuroscience and society through critical practice**. *Biosocieties* 2009, **4**:61-77. doi:10.1017/S1745855209006437.Cohen PD et al.: **Ethical issues in clinical neuroscience research: a patient's perspective.***Neurotherapeutics* 2007, **4**(3): 537-544. doi: 10.1016/j.nurt.2007.04.008.Crozier S: **\[Neuroethics: ethical issues in neurosciences\]**. *Rev Prat* 2013, **63**(5): 666-669.Decker M, Fleischer T: **Contacting the brain---aspects of a technology assessment of neural implants**. *Biotechnol J* 2008, **3**(12): 1502-1510. doi: 10.1002/biot.200800225.Di Luca M et al.: **Consensus document on European brain research**. *Eur J Neurosci* 2011, **33**(5):768-818. doi: 10.1111/j.1460-9568.2010.07596.x.Eaton ML, Illes J: **Commercializing cognitive neurotechnology\--the ethical terrain**. *Nat Biotechnol* 2007, **25**(4): 393-397. doi:10.1038/nbt0407-393.Farah MJ: **Neuroethics: the practical and the philosophical**. *Trends Cogn Sci* 2005, **9**(1): 34-40. doi: 10.1016/j.tics.2004.12.00.Farah MJ: **Social, legal, and ethical implications of cognitive neuroscience: "neuroethics" for short**. *J Cogn Neurosci* 2007, **19**(3): 363-4. doi: 10.1162/jocn.2007.19.3.363.Fellows LK, Stark M, Berg A, Chatterjee A: **Patient registries in cognitive neuroscience research: advantages, challenges, and practical advice**. *J Cogn Neurosci* 2008, **20**(6): 1107-1113. doi: 10.1162/jocn.2008.20065.Fins JJ: **From psychosurgery to neuromodulation and palliation: history's lessons for the ethical conduct and regulation of neuropsychiatricresearch**. *Neurosurg Clin N Am* 2003, **14**(2): 303-19. doi: 10.1016/S1042-3680(02)00118-3.Fischer MMJ: **The BAC \[bioethics advisory committee\] consultation on neuroscience and ethics: an anthropologist's perspective**. *Innovation* 2013, **11**(2): 3-5.Ford PJ: **Special section on clinical neuroethics consultation: introduction**. *HEC Forum* 2008, **20**(3): 311-4. doi: 10.1007/s10730-008-9081-6.Fry CL: **A descriptive social neuroethics is needed to reveal lived identities**. *Am J Bioeth* 2009, **9**(9): 16-7. doi: 10.1080/15265160903098580Fuchs T: **Ethical issues in neuroscience**. *Curr Opin Psychiatry* 2006, **19**(6): 600-607. doi: 10.1097/01.yco.0000245752.75879.26.Fukushi T, Sakura O, Koizumi H: **Ethical considerations of neuroscience research: the perspectives on neuroethics in Japan**. *Neurosci Res* 2007, **57**(1): 10-16. doi: 10.1016/j.neures.2006.09.004.Fukushi T, Sakura O: **Exploring the origin of neuroethics: from the viewpoints of expression and concepts**. *Am J Bioeth* 2008, **8**(1): 56-57. doi: 10.1080/15265160701839672.Fukushi T, Sakura O: **\[Introduction of neuroethics: out of clinic, beyond academia in human brain research\]**. *Rinsho Shinkeigaku* 2008, **48**(11): 952-954. doi: 10.5692/clinicalneurol.48.952.Galpern WR et al.: **Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations**. *Lancet Neurol* 2012, **11**(7): 643-650. doi: 10.1016/S1474-4422(12)70064-9.Glannon W: **Neuroethics**. *Bioethics* 2006, **20**(1): 37-52. doi: 10.1111/j.1467-8519.2006.00474.x.Gray JR, Thompson PM: **Neurobiology of intelligence: science and ethics**. *Nat Rev Neurosci* 2004, **5**(6): 471-482. doi: 10.1038/nrn1405.Gutiérrez G: **Neurobiología y contenido material universal de la ética: reflexiones a partir del modelo neurobiológico de Antonio Damasio**. *Utop Prax Latinoam* 2006, **11**(33): 9-38.Hauser SL: **What ethics integration looks like in neuroscience research**. *Ann Neurol* 2014, **75**(5): 623-624. doi: 10.1002/ana.24177.Henry S, Plemmons D: **Neuroscience, neuropolitics and neuroethics: the complex case of crime, deception and FMRI**. *Sci Eng Ethics* 2012, **18**(3): 573-591. doi: 10.1007/s11948-012-9393-4.Illes J: **Empirical neuroethics: can brain imaging visualize human thought? why is neuroethics interested in such a possibility?***EMBO Rep* 2007, **8**: S57-S60. doi: 10.1038/sj.embor.7401007.Illes J: **Empowering brain science with neuroethics**. *Lancet* 2010, **376**(9749): 1294-1295. doi: 10.1016/S0140-6736(10)61904-6.Illes J et al.: **International perspectives on engaging the public in neuroethics**. *Nat Rev Neurosci* 2005, **6**(12): 977-982. doi:10.1038/nrn1808.Illes J, Raffin TA: **Neuroethics: an emerging new discipline in the study of brain and cognition**. *Brain Cogn* 2002, **50**(3): 341-344. doi: 10.1016/s0278-2626(02)00522-5.Illes J, Bird SJ: **Neuroethics: a modern context for ethics in neuroscience**. *Trends Neurosci* 2006, **29**(9): 511-517. doi: 10.1016/j.tins.2006.07.002.Illes J et al.: **Neurotalk: improving the communication of neuroscience research**. *Nat Rev Neurosci* 2010, **11**(1): 61-69. doi: 10.1038/nrn2773.Illes J et al.: **Reducing barriers to ethics in neuroscience**. *Front Hum Neurosci* 2010, **4**: 167. doi: 10.3389/fnhum.2010.00167.Jonsen AR: **What it means to "map" the field of neuroethics**. *Cerebrum* 2002, **4**(3): 71-72.Jox RJ, Schöne-Seifert B, Brukamp K: **\[Current controversies in neuroethics\]**. *Nervenarzt* 2013, **84**(10):1163-1164. doi: 10.1007/s00115-013-3731-x.Justo L, Erazun F: **Neuroethics needs an international human rights deliberative frame.***AJOB Neurosci* 2010, **1**(4): 17-18. doi: 10.1080/21507740.2010.515559.Kirschenbaum SR: **Patenting basic research: myths and realities**. *Nat Neurosci* 2002, **5**: Suppl 1025-1027. doi: 10.1038/nn932.Klein E: **Is there a need for clinical neuroskepticism?***Neuroethics* 2011, **4**(3): 251-259. doi: 10.1007/s12152-010-9089-xKretzschmar H: **Brain banking: opportunities, challenges and meaning for the future**. *Nat Rev Neurosci* 2009, **10**(1): 70-78. doi: 10.1038/nrn2535.Labuzetta JN, Burnstein R, Pickard J: **Ethical issues in consenting vulnerable patients for neuroscience research**. *J Psychopharmacol* 2011, **25**(2): 205-210. doi: 10.1177/0269881109349838.Lanzilao E, Shook JR, Benedikter R, Giordano J: **Advancing neuroscience on the 21st-century world stage: the need for and a proposed structure of an internationally relevant neuroethics**. *Ethics Biol Eng Med* 2013, **4**(3), 211-229. doi: 10.1615/EthicsBiologyEngMed.2014010710.Leonardi M et al.: **Pain, suffering and some ethical issues in neuroscience research**. *J Headache Pain* 2004, **5**(2): 162-164. doi: 10.1007/s10194-004-0088-3.Leshner AI: **Ethical issues in taking neuroscience research from bench to bedside.***Cerebrum* 2004, **6**(4): 66-72.Lieberman MD: **Social cognitive neuroscience: a review of core processes**. *Annu Rev Psychol* 2007, **58**: 259-289. doi: 10.1146/annurev.psych.58.110405.085654.Lombera S, Illes J: **The international dimensions of neuroethics**. *Dev World Bioeth* 2009, **9**(2):57-64. doi: 10.1111/j.1471-8847.2008.00235.x.Mandel RJ, Burger C: **Clinical trials in neurological disorders using AAV vectors: promises and challenges**. *Curr Opin Mol Ther* 2004, **6**(5):482-490.Mauron A: **\[Neuroethics\]**. *Rev Med Suisse* 2006, **2**(74): 1816.Miller FG, Kaptchuk TJ: **Deception of subjects in neuroscience: an ethical analysis**. *J Neurosci* 2008, **28**(19): 4841-4843. doi: 10.1523/JNEUROSCI.1493-08.2008.Morein-Zamir S, Sahakian BJ: **Neuroethics and public engagement training needed for neuroscientists**. *Trends Cogn Sci* 2010, **14**(2): 49-51. doi: 10.1016/j.tics.2009.10.007.Northoff G: **\[Methodological deficits in neuroethics: do we need theoretical neuroethics?\]**. *Nervenarzt* 2013, **84**(10):1196-1202. doi: 10.1007/s00115-013-3732-9.Nutt DJ, King LA, Nichols DE: **Effects of Schedule 1 drug laws on neuroscience research and treatment innovation**. *Nat Rev Neurosci* 2013, **14**(8): 577-585. doi: 10.1038/nrn3530.Olesen J: **Consensus document on European brain research**. *J Neurol Neurosurg Psychiatry* 2006, **77** (Supp 1):i1-i49.Parens E, Johnston J: **Does is make any sense to speak of neuroethics: three problems with keying ethics to hot new science and technology**. *EMBO Rep* 2007, **8**: S61-S64. doi:10.1038/sj.embor.7400992.Parker LS, Kienholz ML: **Disclosure issues in neuroscience research**. *Account Res* 2008, **15**(4): 226-241. doi: 10.1080/08989620802388697.Paylor B, Longstaff H, Rossi F, Illes J: **Collision or convergence: beliefs and politics in neuroscience discovery, ethics, and intervention**. *Trends Neurosci* 2014, **37**(8): 409-412. doi: 10.1016/j.tins.2014.06.001.Perrachione TK, Perrachione JR: **Brains and brands: developing mutually informative research in neuroscience and marketing**. *J Consumer Behav* 2008, **7**: 303-318. doi: 10.1002/cb.253.Pfaff DW, Kavaliers M, Choleris E: **Response to Peer Commentaries on Mechanisms Underlying an Ability to Behave Ethically---Neuroscience Addresses Ethical Behaviors: Transitioning From Philosophical Dialogues to Testable Scientific Theories of Brain and Behavior**. *Am J Bioeth* 2008, **8**(5): W1-W3. doi: 10.1080/15265160802180117.Pickersgill M: **Ordering disorder: knowledge production and uncertainty in neuroscience research**. *Sci Cult (Lond)* 2011, **20**(1): 71-87. doi: 10.1080/09505431.2010.508086.Pierce R: **What a tangled web we weave: ethical and legal implications of deception in recruitment**. *Account Res* 2008, **15**(4): 262-282. doi: 10.1080/08989620802388713.Racine E, Waldman S, Rosenberg J, Illes J: **Contemporary neuroscience in the media**. *Soc Sci Med* 2010, **71**(4): 725-733. doi: 10.1016/j.socscimed.2010.05.017.Racine E: **Identifying challenges and conditions for the use of neuroscience in bioethics**. *Am J Bioeth* 2007, **7**(1): 74-76. doi: 10.1080/15265160601064363.Racine E, Illes J: **Responsabilités neuroéthiques/neuroethical responsibilities**. *Can J Neurol Sci* 2006, **33**(3): 260-268, 269-277. doi: 10.1017/S0317167100005126.Ramos-Zúñiga R: **\[Neuroethics as a new epistemological perspective in neuroscience\]**. *Rev Neurol* 2014, **58**(4): 145-146.Robillard JM et al.: **Untapped ethical resources for neurodegeneration research**. *BMC Med Ethics* 2011, **12**: 9. doi: 10.1186/1472-6939-12-9.Rose N: **The human brain project: social and ethical challenges**. *Neuron* 2014, **82**(6):1212-1215. doi:10.1016/j.neuron.2014.06.001.Rose N: **The human sciences in a biological age**. *Theory Cult Soc* 2013, **30**(1): 3-34. doi: 10.1177/0263276412456569.Roskies A: **Neuroethics for the new millenium**. *Neuron* 2002, **35**(1): 21-23. doi: 10.1016/S0896-6273(02)00763-8.Schreiber D: **On social attribution: implications of recent cognitive neuroscience research for race, law, and politics**. *Sci Eng Ethics* 2012, **18**(3): 557-566. doi: 10.1007/s11948-012-9381-8.Shook JR, Giordano J: **A principled and cosmopolitan neuroethics: considerations for international relevance**. *Philos Ethics Humanit Med* 2014, **9**:1. doi: 10.1186/1747-5341-9-1.Stevenson S et al.: **Neuroethics, confidentiality, and a cultural imperative in early onset Alzheimer's disease: a case study with a First Nation population**. *Philos Ethics Humanit Med* 2013, **8**: 15. doi: 10.1186/1747-5341-8-15.Synofzik M: **Interventionen zwischen gehirn und geist: eine ethische analyse der neuen moglichkeiten der neurowissenschaften \[Intervening between brain and mind: an ethical analysis of the new possibilities of the neurosciences\]**. *Fortschr Neurol Psychiatr* 2005, **73**(10):596-604. doi:10.1055/s-2004-830292.Swift TL: **Sham surgery trial controls: perspectives of patients and their relatives**. *J Empir Res Hum Res Ethics* 2012, **7**(3): 15-28. doi: 10.1525/jer.2012.7.3.15.Weisberg DS et al.: **The seductive allure of neuroscience explanations**. *J Cogn Neurosci* 2008, **20**(3): 470-477. doi: 10.1162/jocn.2008.20040.Winslade W: **Severe brain injury: recognizing the limits of treatment and exploring the frontiers of research**. *Camb Q Healthc Ethics* 2007, **16**(2): 161-168. doi: 10.1017/S0963180107070181.Wolpe PR: **Ethics and social policy in research on the neuroscience of human sexuality**. *Nature Neuroscience* 2004, **7**(10): 1031-1033. 10.1038/nn1324.Zimmerman E, Racine E: **Ethical issues in the translation of social neuroscience: a policy analysis of current guidelines for public dialogue in human research**. *Account Res* 2012, **19**(1): 27-46. doi: 10.1080/08989621.2012.650949.
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Discussion and conclusions {#Sec4}
==========================

As demonstrated by this bibliography, the breadth and depth of the literature addressing the "ethics of neuroscience" is extensive. Indeed, many of the ethical issues fostered by brain science affect the foci, scope and conduct of clinical care, as much of neuroscientific and neurotechnological research is oriented and being explicitly directed toward translational applications in medicine. In the clinical milieu, the use of various neuroscientific approaches and tools evokes additional, and frequently more provocative, if not contentious issues, questions, problems and debates, and calls forth possible solutions that are specific to patient care, and the execution and sustainability of both (neuro)science and medicine as viable and valuable public good(s). Literature addressing such applications of brain science will be presented in Part 4 of this bibliographic series.
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